Keith S. Manchester net worth and biography

Keith Manchester Biography and Net Worth

Director of Roivant Sciences

Keith Manchester has served as Director of Roivant since 2014. He serves as a Partner and the Head of Life Sciences at QVT Financial, New York, USA, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life science companies. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs & Co. He received his A.B. from Harvard College and his M.D. from Harvard Medical School. Dr. Manchester serves as a director for the following companies: Roivant Sciences Ltd., Roivant Sciences, Inc., Arbutus Biopharma Corporation, and Kriya Therapeutics. Dr. Manchester also sits on the Supervisory Board of Medigene AG.

What is Keith S. Manchester's net worth?: The estimated net worth of Keith S. Manchester is at least $16.34 million as of September 24th, 2024. Dr. Manchester owns 1,412,126 shares of Roivant Sciences stock worth more than $16,338,298 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Manchester may own. Learn More about Keith S. Manchester's net worth.
How do I contact Keith S. Manchester?: The corporate mailing address for Dr. Manchester and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at [email protected]. Learn More on Keith S. Manchester's contact information.
Has Keith S. Manchester been buying or selling shares of Roivant Sciences?: Keith S. Manchester has not been actively trading shares of Roivant Sciences during the last quarter. Most recently, Keith S. Manchester sold 368,052 shares of the business's stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $11.62, for a transaction totalling $4,276,764.24. Following the completion of the sale, the director now directly owns 1,412,126 shares of the company's stock, valued at $16,408,904.12. Learn More on Keith S. Manchester's trading history.
Who are Roivant Sciences' active insiders?: Roivant Sciences' insider roster includes Matthew Gline (CEO), Rakhi Kumar (CAO), Keith Manchester (Director), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.
Are insiders buying or selling shares of Roivant Sciences?: In the last year, insiders at the sold shares 9 times. They sold a total of 7,186,843 shares worth more than $82,463,515.47. The most recent insider tranaction occured on December, 18th when CIO Mayukh Sukhatme sold 412,584 shares worth more than $4,971,637.20. Insiders at Roivant Sciences own 7.9% of the company. Learn More about insider trades at Roivant Sciences.
Information on this page was last updated on 12/18/2024.

Keith S. Manchester Insider Trading History at Roivant Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/24/2024	Sell	368,052	$11.62	$4,276,764.24	1,412,126
9/28/2023	Sell	6,896,144	$11.55	$79,650,463.20	5,023,787

Keith S. Manchester Buying and Selling Activity at Roivant Sciences

Roivant Sciences Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Today's Range

Now: $11.57

$11.41

$11.67

50 Day Range

MA: $11.91

$11.16

$12.71

2 Week Range

Now: $11.57

$9.69

$13.06

Volume

15,754,118 shs

Average Volume

5,795,466 shs

Market Capitalization

$8.42 billion

P/E Ratio

2.05

Dividend Yield

N/A

Beta

1.25

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.